Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
06:49am, Monday, 09'th Dec 2024
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali Starts Dosing in Phase II Parkinson's Disease Study
10:50am, Friday, 06'th Dec 2024
DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.
Denali Has A Neurodegenerative Edge Despite Market Skepticism
08:56am, Saturday, 16'th Nov 2024
Denali Therapeutics' unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company's strong cash positio
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
11:10am, Friday, 08'th Nov 2024
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
04:01pm, Wednesday, 06'th Nov 2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided bus
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:06am, Tuesday, 29'th Oct 2024
Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength?
12:26pm, Monday, 16'th Sep 2024
Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more
Denali Plans to File for Accelerated Approval of Hunter Syndrome Drug
12:41pm, Wednesday, 04'th Sep 2024
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the outcome of a recent successful meeting with the Center for Drug Evaluation a
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
10:55pm, Monday, 19'th Aug 2024
Denali Therapeutics' proprietary Transport Vehicle technology enables drug delivery across the blood-brain barrier, targeting neurodegenerative diseases. DNL310, targeting MPS II, and DNL343 for ALS a
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration
02:00pm, Wednesday, 14'th Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
Wall Street Analysts Believe Denali Therapeutics (DNLI) Could Rally 79.62%: Here's is How to Trade
10:55am, Tuesday, 06'th Aug 2024
The consensus price target hints at a 79.6% upside potential for Denali Therapeutics (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
06:45am, Thursday, 01'st Aug 2024
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cro
Denali Therapeutics (DNLI) Stock Jumps 9.7%: Will It Continue to Soar?
07:16am, Tuesday, 23'rd Jul 2024
Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price in
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
07:09pm, Monday, 08'th Jul 2024
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
